Sab Biotherapeutics, Inc.
About
3.57USD-0.03 -0.83%
Closed • Updated at 04:32 GMT+00:00Market Cap$272.98M
Volume133.8K
Beta0.04
RSI44.82
Sab Biotherapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 5 2026
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
Apr 29 2026
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Apr 22 2026
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Apr 15 2026
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
Mar 19 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Recent Videos
"SAB-142 Didn't Just Stop the T1D Immune Attack. Three Patients Actually Improved."
May 24, 2026
The Immune System's Worst Nightmare: SAB-142's Phase 1 Results #ImmuneSystem #T1D
May 23, 2026
NEET Mai Sab Bio Hack se aya #neet2026 #neet
May 08, 2026
SAB Biotherapeutics: Revolutionizing Diabetes Treatment! ##DiabetesTreatment #InsulinProduction
Apr 06, 2026
Community Chat
Ask AI
Try asking